Service Revenue was Adaptive Biotechnologies’s largest revenue line in fiscal 2025, bringing in $192.83M of $276.98M (70%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Service Revenue | $81.14M | $102.74M | $133.03M | $192.83M | |||||
| Collaboration Revenue | $66.39M | $42.58M | $13.45M | $41.28M | |||||
| Sequencing Revenue | — | — | — | — | |||||
| Service & Licensing Revenue | — | $24.96M | — | $23.36M | |||||
| Development Support Revenue | — | — | — | — | |||||
| Development Revenue | — | — | — | — | |||||
| Immune Medicine Service Revenue | $700.00K | — | $20.00M | — | |||||
| Regulatory Milestone Revenue | $6.00M | — | $12.50M | $19.50M | |||||
| Development Revenue Regulatory Milestones | — | — | — | — | |||||
| Total | $154.23M | $170.28M | $178.98M | $276.98M |
Adaptive Biotechnologies brought in $276.98M from its four revenue lines in fiscal 2025, the year ended December 31, 2025. Adaptive Biotechnologies regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $178.98M. Service Revenue was the largest at $192.83M (69.6%), ahead of Collaboration Revenue at $41.28M (14.9%) and Service & Licensing Revenue at $23.36M (8.4%). The remaining revenue line, Regulatory Milestone Revenue, brought in $19.50M.
Compared with fiscal 2024, Collaboration Revenue grew fastest, up 206.9% to $41.28M. Every revenue line above 2% of revenue grew.
Adaptive Biotechnologies began breaking out Service & Licensing Revenue in fiscal 2023, when it brought in $24.96M. Adaptive Biotechnologies stopped reporting Immune Medicine Service Revenue as a separate revenue line after fiscal 2024, when it brought in $20.00M.
Mrd Revenue was Adaptive Biotechnologies’s largest revenue line in fiscal 2025, bringing in $212.33M of $254.42M (83%).
| Type Of Arrangement | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Mrd Revenue | $81.14M | — | — | $102.74M | $145.53M | $212.33M | ||
| Immune Medicine Revenue | $66.39M | — | — | $67.54M | $13.45M | $41.28M | ||
| Genentech Collaboration Agreement | — | $7.70M | $7.70M | — | — | — | ||
| Medicare Reimbursements | $5.20M | — | — | $700.00K | $6.50M | — | ||
| Cancelled Customer Contracts | — | — | — | $600.00K | $1.20M | $800.00K | ||
| Total | $152.73M | $7.70M | $7.70M | $171.58M | $166.68M | $254.42M |
Adaptive Biotechnologies brought in $254.42M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. That is less than the $276.98M it reports by collaborative arrangement and arrangement other than collaborative, so these revenue lines do not cover all of its revenue. Mrd Revenue was the largest at $212.33M (83.5%), ahead of Immune Medicine Revenue at $41.28M (16.2%) and Cancelled Customer Contracts at $800.00K (0.3%).
Compared with fiscal 2024, Immune Medicine Revenue grew 206.9% to $41.28M and Mrd Revenue grew 45.9% to $212.33M. Some of that change comes from Adaptive Biotechnologies regrouping its revenue lines.
Adaptive Biotechnologies began breaking out Cancelled Customer Contracts in fiscal 2023, when it brought in $600.00K. Adaptive Biotechnologies stopped reporting Genentech Collaboration Agreement ($7.70M in fiscal 2023) and Medicare Reimbursements ($6.50M in fiscal 2024) as separate revenue lines.
Adaptive Biotechnologies (ADPT) reports its revenue by collaborative arrangement and arrangement other than collaborative and by type of arrangement. In fiscal 2025, Service Revenue was its largest revenue line, bringing in $192.83M (69.6% of the total), followed by Collaboration Revenue at $41.28M (14.9%).
Service Revenue was Adaptive Biotechnologies' largest revenue line in fiscal 2025, bringing in $192.83M, or 69.6% of the $276.98M total across its four revenue lines.
Every figure comes from Adaptive Biotechnologies' annual financial filings, as reported. Each line keeps the name Adaptive Biotechnologies gives it, and years follow its fiscal calendar.
Adaptive Biotechnologies' revenue by collaborative arrangement and arrangement other than collaborative goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.